Skip to main content
Journal cover image

Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?

Publication ,  Journal Article
Doraiswamy, PM; Krishnan, KRR; Anand, R; Sohn, H; Danyluk, J; Hartman, RD; Veach, J
Published in: Prog Neuropsychopharmacol Biol Psychiatry
May 2002

Goals of the study included evaluating the long-term efficacy of rivastigmine in Alzheimer's disease (AD) patient categories stratified by baseline dementia severity, and post hoc investigation of particular benefits of early initiation of rivastigmine treatment in moderately severe AD. Both rivastigmine-treated groups (originally randomized to 1-4 or 6-12 mg/day) experienced significantly smaller declines in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores from baseline than the projected placebo group after 52 weeks. Patients receiving rivastigmine from Day 1 experienced significantly less decline compared with patients originally receiving placebo and then initiating rivastigmine treatment after a 6-month delay. Furthermore, cognitive benefits were more robust in patients with moderately severe disease compared with previous reports in mild to moderately severe AD. Findings suggest that early treatment with rivastigmine 6-12 mg/day is associated with sustained long-term cognitive benefits in patients with moderately severe AD. The results support the value of early treatment of AD patients, particularly those with moderately severe AD.

Duke Scholars

Published In

Prog Neuropsychopharmacol Biol Psychiatry

DOI

ISSN

0278-5846

Publication Date

May 2002

Volume

26

Issue

4

Start / End Page

705 / 712

Location

England

Related Subject Headings

  • Time
  • Rivastigmine
  • Psychiatry
  • Phenylcarbamates
  • Male
  • Humans
  • Female
  • Double-Blind Method
  • Carbamates
  • Analysis of Variance
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Doraiswamy, P. M., Krishnan, K. R. R., Anand, R., Sohn, H., Danyluk, J., Hartman, R. D., & Veach, J. (2002). Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry, 26(4), 705–712. https://doi.org/10.1016/s0278-5846(01)00326-8
Doraiswamy, P Murali, K Ranga Rama Krishnan, Ravi Anand, Hyesung Sohn, Jacquiline Danyluk, Richard D. Hartman, and Jeffrey Veach. “Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?Prog Neuropsychopharmacol Biol Psychiatry 26, no. 4 (May 2002): 705–12. https://doi.org/10.1016/s0278-5846(01)00326-8.
Doraiswamy PM, Krishnan KRR, Anand R, Sohn H, Danyluk J, Hartman RD, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry. 2002 May;26(4):705–12.
Doraiswamy, P. Murali, et al. “Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?Prog Neuropsychopharmacol Biol Psychiatry, vol. 26, no. 4, May 2002, pp. 705–12. Pubmed, doi:10.1016/s0278-5846(01)00326-8.
Doraiswamy PM, Krishnan KRR, Anand R, Sohn H, Danyluk J, Hartman RD, Veach J. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry. 2002 May;26(4):705–712.
Journal cover image

Published In

Prog Neuropsychopharmacol Biol Psychiatry

DOI

ISSN

0278-5846

Publication Date

May 2002

Volume

26

Issue

4

Start / End Page

705 / 712

Location

England

Related Subject Headings

  • Time
  • Rivastigmine
  • Psychiatry
  • Phenylcarbamates
  • Male
  • Humans
  • Female
  • Double-Blind Method
  • Carbamates
  • Analysis of Variance